Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 185Myelodysplastic Syndromes 82Leukemia 39Leukemia, Myelomonocytic, Chronic 36Recurrence 24Myeloproliferative Disorders 15Congenital Abnormalities 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Neoplasms 11Primary Myelofibrosis 9Melanoma 9Blast Crisis 9Thrombocythemia, Essential 7Polycythemia Vera 7Leukemia, Myelomonocytic, Acute 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Monocytic, Acute 7Hodgkin Disease 7Carcinoma, Non-Small-Cell Lung 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Ovarian Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 6Anemia, Refractory, with Excess of Blasts 6Neoplasm Metastasis 5Lymphoma 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Biphenotypic, Acute 5Lymphoma, Non-Hodgkin 4Lung Neoplasms 4

Interventions

Nivolumab 143pembrolizumab 129Sunitinib 127Bevacizumab 71Everolimus 70Sorafenib 68cabozantinib 64Ipilimumab 61pazopanib 58Axitinib 57aldesleukin 51Magnetic Resonance Spectroscopy 43Cyclophosphamide 40Interleukin-2 38lenvatinib 36Radiosurgery 36Specimen Handling 33Interferon-alpha 32atezolizumab 29belzutifan 24temsirolimus 23Gemcitabine 23fludarabine phosphate 22Radiotherapy 18Interferon alpha-2 18Biopsy 18fludarabine 17durvalumab 17avelumab 17Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Renal Cell × Decitabine × Clear all
NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Terminated
252 enrolled 67 charts
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04049344 2019-08-08

Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma

Zhejiang Cancer Hospital

Phase 2 Unknown
25 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00561912 2011-12-26

Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled 3 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡